-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | Pick up Bay
On April 27, the CDE official website showed that the clinical trial application for the EX103 injection of the CD20/CD3 bispecific antibody from Esmilion was accepted by the NMPA.
EX103 is developed using ExMab, a four-chain bispecific antibody platform from Esmin Biotech.
The EX103 of ASM Biologics is the fourth CD20/CD3 bispecific antibody to be declared clinically in China.
Roche developed a new type of "2:1" double antibody against glofitamab, which contains 2 Fabs that bind CD20 and 1 Fab that binds CD3.
mosunetuzumab is another CD3/CD20 double antibody developed by Luo.
REGN1979 was developed by Regeneron.
REGN1979
Domestic companies, Nuocheng Jianhua, Jiahe Biological, and Bojin Biological have also deployed CD20/CD3 dual antibodies, which are currently in the preclinical development stage.